Navigation Links
Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement
Date:3/17/2008

ATLANTA and BOSTON, March 17 /PRNewswire-FirstCall/ -- Alimera Sciences and pSivida Ltd (Nasdaq: PSDV; ASX: PSD; Xetra: PSI) today announced that they have amended their license and collaboration agreement relating to Medidur(TM) FA, the companies' Phase III investigative treatment for diabetic macular edema (DME), and other Medidur products. Alimera is increasing its equity in the future profits of Medidur FA from 50 to 80 percent in exchange for consideration of up to approximately $78m to pSivida.

Consideration to pSivida includes an up-front payment of $12m, a $25m milestone payment upon FDA approval of Medidur(TM) FA, other payments of up to approximately $21m by September 30, 2012, and assumption of pSivida's research and development funding obligations estimated at approximately $20m.

"We are very pleased with this agreement as it provides us with the opportunity to increase our stake and consolidate the development and commercialization of our late stage DME product Medidur FA," said Dan Myers, President and CEO of Alimera Sciences. "In addition, we will further advance the delivery system's application in other serious ophthalmic conditions like dry age-related macular degeneration (AMD), using exploratory treatments such as the groundbreaking work we are doing around NADPH oxidase inhibitors."

"We believe this is a great deal for pSivida and its shareholders as it gives the company a significant financial interest in very exciting products and economics that eliminate our need for equity financing for the foreseeable future under our current plans," said pSivida Managing Director, Dr. Paul Ashton. "This new agreement with Alimera Sciences is expected to significantly reduce our burn rate going forward as the
'/>"/>

SOURCE Alimera Sciences
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
2. Pressure BioSciences, Inc. to Discuss 2007 Financial Results and Provide Business Update
3. DARA BioSciences, Inc. Announces Appointment of New Director to Board
4. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration
5. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
6. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
7. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
8. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
9. Pressure BioSciences, Inc. Provides Corporate Update
10. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
11. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...f., Nov. 6 Intarcia Therapeutics, ... 650 (DUROS® continuous delivery of exenatide...the Ninth Annual Diabetes Technology Meeting in Sa...com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,, Co...CA 650 Lowers Plasma Glucose, HbA1c and Reduces We...
(Date:11/5/2009)...olo., Nov. 5 The endangered black-...stern U.S. This rare carnivore feeds on prairie d...ague and often entire population die-offs in towns...) has implemented a ferret breeding program and ha...ir formerly native habitat. Unfortunately, plague...
(Date:11/5/2009)...ll on Thursday, November 5, 2009 at 4:30 p.m. East...PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals,...I ) today reported unaudited financial results for... 30, 2009 and reviewed the Company,s highlights fo...onsolidated results reflect the operations of Onco...
(Date:11/5/2009)...exas, Nov. 5 Wound Manag...that it has entered into a Letter of Intent to pur...lth Technologies, Inc. (OTC Bulletin Board: VHGI)....in cash and debt, 4,000,000 shares of WNDM and a r... the Veriscrip technology being acquired from VHGI...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3
...sia/ -- Simcere Pharmaceutical Group,("Simcere" or...urer and supplier,of branded generic and innovativ...ed financial results for the quarter ended March 3...creased to RMB442.5 million (US$64.8 million) for ...lion for the corresponding, period in 2008, ...
...ls announces it has signed an agreement with HUYA ... enabling and accelerating global codevelopment of...ginating in China. , , Through this agreement, S...omprehensive Chinese molecule portfolio, focusing ...ea. As some of these molecules are already in adv...
...oratories, Inc., an emerging specialty pharmaceuti...ausea and vomiting (OINV) in opioid pharmaceutical... Exploratory Bioequivalence Study on CL-108, Charl...ising data on our immediate-release low-dose antie...icer at Charleston Laboratories, "and confirm our ...
Other Biology Technology:Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 2Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 3Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 4Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 5Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 6Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 7Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 8Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 9Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 10Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 11Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China 2Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China 3Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108 2
(Date:11/5/2009)...n, Conn.Researchers at Yale University have develo...ody,s immune response to HIV and HIV-infected cell...ings, published online in the Journal of the Amer...eutic approaches for these diseases. , The mole...ing HIV" (ARM-H) and "antibody-recruiting molecule...
(Date:11/4/2009)...PHIA Although scientists are reluctant to officia...d, evidence continues to grow about its protective...ed in Cancer Prevention Research , a journal of t... suggests some reduction in oral cancer. , Vass...ine in the Department of Thoracic/Head and Neck Me...
(Date:11/4/2009)...affic corridors in the cities of Long Beach and Ri...on of preventable childhood asthma, and the true i...isease has likely been underestimated, according t...rnia (USC). , The study, which appears in an on...alth , estimated that nine percent of all childhoo...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2USC study finds big air pollution impacts on local communities 2Any Day OK for Heart Bypass Surgery 58127 1Any Day OK for Heart Bypass Surgery 58127 2Data Strategy Invited to Become a Member of VMware 26apos 3Bs Partner Technical Advisory Board 28PTAB 29 58123 1Data Strategy Invited to Become a Member of VMware 26apos 3Bs Partner Technical Advisory Board 28PTAB 29 58123 2Healthcare Breach Notification Rules Take Effect 3B ID Experts Offers Complimentary Tool to Measure Organizations Breach Index 58119 1Healthcare Breach Notification Rules Take Effect 3B ID Experts Offers Complimentary Tool to Measure Organizations Breach Index 58119 2Healthcare Breach Notification Rules Take Effect 3B ID Experts Offers Complimentary Tool to Measure Organizations Breach Index 58119 3
...reat idea or invention but don,t know where to tur...ing day of four workshops for first-time entrepren...Center and the Alumni Association of NJIT. Set fo...30 a.m. 3 p.m., the event will feature many oppor...ch that dream. , "I Have an Idea, Now What?" is...
...ase, MDCigarette smoking during pregnancy is assoc...ernal and fetal thyroid function, according to a n... Society,s Journal of Clinical Endocrinology & Me...f cigarette smoking on thyroid function of two gro... in the first trimester and the other in the third...
...lle, NY, January 12, 2009The Academy of Breastfeed...ite, Facebook, would be well advised to review its...rs. Such a policy perpetuates the notion that brea... from public viewing, a misguided and antiquated c...It further perpetuates the idea that formula feedi...
Other Biology News:Entrepreneurs wanted for NJIT workshops about how to launch a business 2
Cat IgA ELISA Kit from Bethyl Laboratories
Cat IgM ELISA Kit from Bethyl Laboratories
Phosphatase Colorimetric Assay Kit from BioAssay Systems
Horse IgGb ELISA Kit from Bethyl Laboratories
Biology Products: